The Minimal Residual Disease Testing Market was valued at USD 2.16 billion in 2023 and is expected to reach USD 5.74 billion by 2032, growing at a CAGR of 11.50% over the forecast period of 2024-2032. This report emphasizes the world burden of MRD, examining incidence and prevalence trends that fuel the need for sophisticated diagnostic solutions. The research examines MRD testing patterns in different technologies, such as NGS and flow cytometry, which are becoming must-haves in disease monitoring. Moreover, it considers market penetration and the dynamic reimbursement environment where policies from regulations and insurance play an important role in accessibility as well as affordability. The study further explores clinical trials and drug development with the integration of MRD testing where more pharmaceuticals are using the tests to analyze the effectiveness of their treatments as well as advance the outcomes for their patients.
The U.S. Minimal Residual Disease Testing Market grew at a CAGR of 10.38% over the forecast period of 2024-2032. Within the U.S., the MRD testing market is growing with the increasing prevalence of cancer, broader uptake of personalized medicine, and rising investments in precision oncology, which are encouraged by supportive regulatory environments and healthcare reimbursement schemes.
Drivers
The MRD testing market is being driven by increasing cancer prevalence, rising adoption of precision medicine, and advancements in molecular diagnostics.
By 2040, cancer incidence is estimated to increase by 47% worldwide, driving the need for sophisticated monitoring technologies such as MRD testing, states the WHO. The move toward individualized treatment approaches in cancer therapy has rendered MRD testing an indispensable instrument in planning therapy and forecasting relapse. Next-generation sequencing (NGS) and digital PCR technologies have greatly enhanced test sensitivity, with residual disease being detected earlier. In addition, the increasing use of MRD testing in drug development clinical trials is hastening its adoption. The rise in regulatory approvals, including the FDA's clearance of Adaptive Biotechnologies' ClonoSEQ assay for the detection of MRD in multiple myeloma and lymphoid malignancies, is also propelling market growth. Further, increasing insurance coverage and reimbursement policies in various countries are increasing access to MRD testing for patients. The intense interest of pharma firms in applying MRD as an immunotherapy and targeted therapy effectiveness biomarker further propels market growth. Rising awareness among hematologists and oncologists about the value of MRD testing for better patient outcomes is likely to continue at this pace over the coming years.
Restraints
The MRD testing market faces key restraints, including high costs, limited standardization, and regulatory hurdles.
MRD testing by NGS or digital PCR is costly, with test prices between USD 1,000 and USD 5,000 per patient, and hence less accessible in low-income groups. Furthermore, the absence of universal standardization across MRD detection techniques results in heterogeneity of test results, reducing clinical confidence in its extensive use. Although flow cytometry is still the most popular technique, it is less sensitive than molecular-based methods, introducing discrepancies in MRD measurement. Regulatory hurdles also present a challenge since MRD assay approvals vary by region, resulting in delayed commercialization. For instance, although ClonoSEQ has obtained FDA approval, other MRD assays are still going through intense regulatory scrutiny in other markets. In addition, reimbursement policies are quite different, with some insurers reimbursing MRD testing for only certain indications, which restricts its wider clinical application. There is also limited awareness and training among healthcare providers for interpreting MRD results, which prevents its inclusion in routine clinical practice. The need for specialized laboratory facilities and expertise to conduct MRD testing also limits its widespread use, particularly in resource-limited healthcare systems.
Opportunities
The expansion of MRD applications in solid tumors, advancements in liquid biopsy technology, and increasing collaborations between biotech companies and pharmaceutical firms.
Although MRD testing has been most commonly applied in hematologic malignancies, recent studies indicate its promise in solid tumors like breast, colorectal, and lung cancers. MRD detection using circulating tumor DNA (ctDNA) analysis has been demonstrated to predict relapse several months before traditional imaging, paving the way for market expansion. Another huge opportunity comes from the increased use of liquid biopsy-based MRD tests that are non-invasive, ultra-sensitive, and in real time to monitor the recurrence of cancer. Guardant Health and Natera, among other firms, are developing liquid biopsies as MRD detectors. The escalating use of MRD testing within pharma R&D for measuring the response of treatments in immunotherapy and targeted therapy trials also drives demand. The increasing focus on AI and machine learning for improving MRD test accuracy and automation adds to the market potential even more. Furthermore, increasing government funding and private investment in cancer diagnostics are preparing a conducive climate for the development and commercialization of advanced MRD assays, which are making early detection more accessible and economical.
Challenges
The MRD testing market faces significant challenges, including technical limitations, sample collection difficulties, and clinical validation issues.
One of the significant challenges is the need for sensitive and specific detection techniques to detect minimal residual disease accurately. Although NGS and digital PCR provide high sensitivity, they demand good-quality DNA/RNA samples, which are not always easy to obtain, particularly in solid tumors. Moreover, the heterogeneity of MRD levels among patients poses challenges in establishing standardized cut-offs for therapeutic decisions. A major hurdle in MRD testing is the problem of false positives or false negatives, which can affect clinical decision-making and result in overtreatment or undertreatment. The collection and processing of samples also present logistical problems since MRD determination necessitates serial testing over time to follow disease progression. The deficiency of long-term clinical proof-of-concept studies that show the effect of MRD-directed treatment decisions on overall survival also hinders adoption. Additionally, the hesitancy of some oncologists to embrace MRD testing as a routine part of their clinical practice because of test accuracy and interpretability concerns constitutes another source of resistance. Overcoming these technical, clinical, and operational issues will be essential to ensure the wider use of MRD testing in oncology.
By Technology
In 2023, the Flow Cytometry segment led the MRD testing market with a market share of more than 40%. This was mainly because it had become very popular in hospital and laboratory environments, was less expensive and easily accessible compared to molecular approaches, and has been traditionally used in hematologic malignancies for residual disease burden detection. The standardized processes and established regulatory approvals for MRD testing using flow cytometry also helped it be at the leadership level.
The Polymerase Chain Reaction (PCR) segment is also expected to be the largest-growing technology in the forecast period. This is due to the higher sensitivity of PCR than that of flow cytometry, greater adoption of real-time and digital PCR technologies, and its growing application in hematologic and solid tumors. With the growing number of FDA-approved PCR-based MRD assays and their capacity to deliver quantifiable and standardized results, they become a preferred choice for clinical as well as research purposes.
By Cancer Type
Hematological Malignancies was the dominant segment in 2023, capturing more than 60% of the overall MRD testing market. This is due to the widespread prevalence of leukemia, lymphoma, and multiple myeloma cases, for which MRD testing is already widely established as a standard tool in disease surveillance and treatment. The availability of well-defined MRD testing guidelines in hematologic cancers and robust reimbursement mechanisms further consolidated this segment's leadership.
The Solid Tumors segment is likely to be the most rapidly growing category in the future. The increasing use of MRD testing in cancers like breast, lung, and colorectal tumors is driving this growth, led by the development of liquid biopsy and next-generation sequencing (NGS) technologies. The growing emphasis on early relapse detection and treatment optimization in solid tumors is broadening the application of MRD testing beyond hematologic cancers.
By Business
The Hospitals and Specialty Clinics segment was the largest market contributor in 2023, with a 45% market share. This was attributed to the large volume of MRD testing in hospital labs, the adoption of MRD testing as a standard part of clinical workflows, and the availability of specialized oncology facilities that are dependent on MRD diagnostics for monitoring treatment. Strong hospital infrastructure and the availability of sophisticated diagnostic technologies also helped this segment lead the market.
The Academic and Research Institutes segment is expected to experience the fastest expansion in the coming years. Growing numbers of MRD-centric clinical trials, growth in government and private sources of funding for cancer research, and innovation in the development of new MRD detection technologies are major drivers propelling the growth of this segment. The contribution of academic institutions in affirming new MRD approaches and their partnerships with biotech firms are also driving growth.
North America led the Minimal Residual Disease (MRD) Testing Market in 2023, with a market share of more than 39.9% globally. The region's leadership was fueled mainly by the prevalence of hematologic malignancies, the robust established reimbursement structures, and the availability of the major market players like Adaptive Biotechnologies, Natera, and Invitae. The U.S. dominated the region with increased investments in oncology diagnostics, high adoption rates of next-generation sequencing (NGS) technologies, and enhanced clinical trial activity incorporating MRD testing. Further, the surging need for precision medicine and strict regulatory clearance by the FDA also bolstered North America's dominance in the MRD market.
Asia-Pacific is anticipated to be the region with the highest growth rate, with a forecast growth rate outpacing other regions during the forecast period. This growth is boosted by the expanding cancer burden, increasing uptake of sophisticated molecular diagnostic technologies, and increasing healthcare infrastructure in nations such as China, Japan, and India. Further, increasing government support, favorable reimbursement environments, and the emergence of international diagnostics players in APAC regions are fueling adoption. The growing trend toward individualized medicine and the rising recognition of liquid biopsy-based MRD testing are additionally driving market expansion in the region.
Exact Sciences Corporation – Oncotype MAP
GRAIL, LLC – Galleri (Developing MRD applications)
Veracyte, Inc.
Natera, Inc. – Signatera
Guardant Health – Guardant Reveal
F. Hoffmann-La Roche Ltd – AVENIO Tumor Tissue Analysis (Exploring MRD applications)
FOUNDATION MEDICINE, INC. – FoundationOne Tracker
QIAGEN – ipsogen MRD Tests
mdxhealth
Bio-Techne – Asuragen QuantideX qPCR Assays
In March 2025, Veracyte, Inc. announced the presentation of multiple abstracts at the 40th Annual European Association of Urology Congress (EAU25), highlighting the clinical performance of its Decipher tests for prostate and bladder cancer.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | USD 2.16 billion |
| Market Size by 2032 | USD 5.74 billion |
| CAGR | CAGR of 11.50% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Technology [Flow Cytometry, Polymerase Chain Reaction (PCR), Next-generation sequencing (NGS), Others] • By Cancer Type [Haematological Malignancy (Leukaemia, Lymphoma), Solid Tumours] • By Business [Hospitals and Speciality Clinics, Diagnostic Laboratories, Academic and Research Institutes, Others] |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Exact Sciences Corporation, GRAIL, LLC, Veracyte, Inc., Natera, Inc., Guardant Health, F. Hoffmann-La Roche Ltd, FOUNDATION MEDICINE, INC., QIAGEN, mdxhealth, Bio-Techne. |
Ans: The Minimal Residual Disease Testing market is projected to grow at a CAGR of 11.50% during the forecast period.
Ans: By 2032, the Minimal Residual Disease Testing market is expected to reach USD 5.74 billion, up from USD 2.16 billion in 2023.
Ans: The MRD testing market is being driven by increasing cancer prevalence, rising adoption of precision medicine, and advancements in molecular diagnostics.
Ans: The MRD testing market faces key restraints, including high costs, limited standardization, and regulatory hurdles.
Ans: North America is the dominant region in the Minimal Residual Disease Testing market.
Table of content
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research & Academic Institutes Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research & Academic Institutes Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Global Burden of Minimal Residual Disease (MRD) - Incidence & Prevalence Trends (2023-2032)
5.2 MRD Testing Utilization Trends, by Technology (2023-2032)
5.3 Market Penetration & Reimbursement Landscape for MRD Testing (2023)
5.4 Clinical Trials & MRD Integration in Drug Development (2023-2032)
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and Promotional Activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Minimal Residual Disease Testing Market Segmentation, by Technology
7.1 Chapter Overview
7.2 Flow Cytometry
7.2.1 Flow Cytometry Market Trends Analysis (2020-2032)
7.2.2 Flow Cytometry Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Polymerase Chain Reaction (PCR)
7.3.1 Polymerase Chain Reaction (PCR) Market Trends Analysis (2020-2032)
7.3.2 Polymerase Chain Reaction (PCR) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Next-generation sequencing (NGS)
7.4.1 Next-generation sequencing (NGS) Market Trends Analysis (2020-2032)
7.4.2 Next-generation sequencing (NGS) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Others
7.5.1 Others Market Trends Analysis (2020-2032)
7.5.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Minimal Residual Disease Testing Market Segmentation, by Cancer Type
8.1 Chapter Overview
8.2 Haematological Malignancy
8.2.1 Haematological Malignancy Market Trends Analysis (2020-2032)
8.2.2 Haematological Malignancy Market Size Estimates and Forecasts to 2032 (USD Billion)
8.2.3 Leukaemia
8.2.3.1 Leukaemia Market Trends Analysis (2020-2032)
8.2.3.2 Leukaemia Market Size Estimates and Forecasts to 2032 (USD Billion)
8.2.4 Lymphoma
8.2.4.1 Lymphoma Market Trends Analysis (2020-2032)
8.2.4.2 Lymphoma Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Solid Tumours
8.3.1 Solid Tumours Market Trends Analysis (2020-2032)
8.3.2 Solid Tumours Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Minimal Residual Disease Testing Market Segmentation, by Business
9.1 Chapter Overview
9.2 Hospitals and Speciality Clinics
9.2.1 Hospitals and Speciality Clinics Market Trends Analysis (2020-2032)
9.2.2 Hospitals and Speciality Clinics Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Diagnostic Laboratories
9.3.1 Diagnostic Laboratories Market Trends Analysis (2020-2032)
9.3.2 Diagnostic Laboratories Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Academic and Research Institutes
9.4.1 Academic and Research Institutes Market Trends Analysis (2020-2032)
9.4.2 Academic and Research Institutes Market Size Estimates and Forecasts to 2032 (USD Billion)
9.5 Others
9.5.1 Others Market Trends Analysis (2020-2032)
9.5.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Minimal Residual Disease Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.2.3 North America Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.2.4 North America Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.2.5 North America Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.2.6.2 USA Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.2.6.3 USA Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.2.7.2 Canada Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.2.7.3 Canada Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.2.8.2 Mexico Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.2.8.3 Mexico Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Trends Analysis
10.3.1.2 Eastern Europe Minimal Residual Disease Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.1.3 Eastern Europe Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.3.1.4 Eastern Europe Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.3.1.5 Eastern Europe Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.3.1.6 Poland
10.3.1.6.1 Poland Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.3.1.6.2 Poland Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.3.1.6.3 Poland Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.3.1.7 Romania
10.3.1.7.1 Romania Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.3.1.7.2 Romania Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.3.1.7.3 Romania Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.3.1.8 Hungary
10.3.1.8.1 Hungary Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.3.1.8.2 Hungary Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.3.1.8.3 Hungary Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.3.1.9 turkey
10.3.1.9.1 Turkey Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.3.1.9.2 Turkey Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.3.1.9.3 Turkey Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.3.1.10 Rest of Eastern Europe
10.3.1.10.1 Rest of Eastern Europe Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.3.1.10.2 Rest of Eastern Europe Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.3.1.10.3 Rest of Eastern Europe Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.3.2 Western Europe
10.3.2.1 Trends Analysis
10.3.2.2 Western Europe Minimal Residual Disease Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.2.3 Western Europe Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.3.2.4 Western Europe Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.3.2.5 Western Europe Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.3.2.6 Germany
10.3.2.6.1 Germany Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.3.2.6.2 Germany Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.3.2.6.3 Germany Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.3.2.7 France
10.3.2.7.1 France Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.3.2.7.2 France Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.3.2.7.3 France Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.3.2.8 UK
10.3.2.8.1 UK Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.3.2.8.2 UK Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.3.2.8.3 UK Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.3.2.9 Italy
10.3.2.9.1 Italy Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.3.2.9.2 Italy Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.3.2.9.3 Italy Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.3.2.10 Spain
10.3.2.10.1 Spain Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.3.2.10.2 Spain Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.3.2.10.3 Spain Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.3.2.11 Netherlands
10.3.2.11.1 Netherlands Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.3.2.11.2 Netherlands Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.3.2.11.3 Netherlands Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.3.2.12 Switzerland
10.3.2.12.1 Switzerland Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.3.2.12.2 Switzerland Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.3.2.12.3 Switzerland Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.3.2.13 Austria
10.3.2.13.1 Austria Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.3.2.13.2 Austria Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.3.2.13.3 Austria Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.3.2.14 Rest of Western Europe
10.3.2.14.1 Rest of Western Europe Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.3.2.14.2 Rest of Western Europe Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.3.2.14.3 Rest of Western Europe Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Minimal Residual Disease Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.4.3 Asia Pacific Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.4.4 Asia Pacific Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.4.5 Asia Pacific Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.4.6.2 China Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.4.6.3 China Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.4.7.2 India Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.4.7.3 India Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.4.8.2 Japan Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.4.8.3 Japan Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.4.9.2 South Korea Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.4.9.3 South Korea Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.4.10 Vietnam
10.4.10.1 Vietnam Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.4.10.2 Vietnam Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.4.10.3 Vietnam Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.4.11 Singapore
10.4.11.1 Singapore Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.4.11.2 Singapore Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.4.11.3 Singapore Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.4.12 Australia
10.4.12.1 Australia Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.4.12.2 Australia Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.4.12.3 Australia Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.4.13 Rest of Asia Pacific
10.4.13.1 Rest of Asia Pacific Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.4.13.2 Rest of Asia Pacific Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.4.13.3 Rest of Asia Pacific Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Middle East
10.5.1.1 Trends Analysis
10.5.1.2 Middle East Minimal Residual Disease Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.1.3 Middle East Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.5.1.4 Middle East Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.5.1.5 Middle East Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.5.1.6 UAE
10.5.1.6.1 UAE Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.5.1.6.2 UAE Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.5.1.6.3 UAE Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.5.1.7 Egypt
10.5.1.7.1 Egypt Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.5.1.7.2 Egypt Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.5.1.7.3 Egypt Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.5.1.8 Saudi Arabia
10.5.1.8.1 Saudi Arabia Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.5.1.8.2 Saudi Arabia Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.5.1.8.3 Saudi Arabia Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.5.1.9 Qatar
10.5.1.9.1 Qatar Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.5.1.9.2 Qatar Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.5.1.9.3 Qatar Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.5.1.10 Rest of Middle East
10.5.1.10.1 Rest of Middle East Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.5.1.10.2 Rest of Middle East Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.5.1.10.3 Rest of Middle East Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.5.2 Africa
10.5.2.1 Trends Analysis
10.5.2.2 Africa Minimal Residual Disease Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.2.3 Africa Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.5.2.4 Africa Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.5.2.5 Africa Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.5.2.6 South Africa
10.5.2.6.1 South Africa Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.5.2.6.2 South Africa Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.5.2.6.3 South Africa Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.5.2.7 Nigeria
10.5.2.7.1 Nigeria Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.5.2.7.2 Nigeria Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.5.2.7.3 Nigeria Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.5.2.8 Rest of Africa
10.5.2.8.1 Rest of Africa Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.5.2.8.2 Rest of Africa Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.5.2.8.3 Rest of Africa Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Minimal Residual Disease Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.6.3 Latin America Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.6.4 Latin America Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.6.5 Latin America Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.6.6.2 Brazil Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.6.6.3 Brazil Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.6.7.2 Argentina Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.6.7.3 Argentina Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.6.8 Colombia
10.6.8.1 Colombia Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.6.8.2 Colombia Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.6.8.3 Colombia Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America Minimal Residual Disease Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.6.9.2 Rest of Latin America Minimal Residual Disease Testing Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Billion)
10.6.9.3 Rest of Latin America Minimal Residual Disease Testing Market Estimates and Forecasts, by Business (2020-2032) (USD Billion)
11. Company Profiles
11.1 Exact Sciences Corporation
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Product / Services Offered
11.1.4 SWOT Analysis
11.2 GRAIL, LLC
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Product / Services Offered
11.2.4 SWOT Analysis
11.3 Veracyte, Inc.
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Product / Services Offered
11.3.4 SWOT Analysis
11.4 Natera, Inc.
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Product / Services Offered
11.4.4 SWOT Analysis
11.5 Guardant Health
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Product / Services Offered
11.5.4 SWOT Analysis
11.6 F. Hoffmann-La Roche Ltd
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Product / Services Offered
11.6.4 SWOT Analysis
11.7 FOUNDATION MEDICINE, INC.
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Product / Services Offered
11.7.4 SWOT Analysis
11.8 QIAGEN
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Product / Services Offered
11.8.4 SWOT Analysis
11.9 mdxhealth
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Product / Services Offered
11.9.4 SWOT Analysis
11.10 Bio-Techne
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Product / Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments
By Technology
Flow Cytometry
Polymerase Chain Reaction (PCR)
Next-generation sequencing (NGS)
Others
By Cancer Type
Haematological Malignancy
Leukaemia
Lymphoma
Solid Tumours
By Business
Hospitals and Speciality Clinics
Diagnostic Laboratories
Academic and Research Institutes
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
The Patient Handling Equipment Market size was estimated at USD 10.94 billion in 2023 and is expected to reach USD 17.85 billion By 2031 at a CAGR of 6.3% during the forecast period of 2024-2031.
The Medical Imaging Workstations Market Size was valued at USD 8.96 Billion in 2023 and is expected to reach USD 15.10 Billion by 2032 and grow at a CAGR of 5.99% over the forecast period 2024-2032.
The Digital Therapeutics Market size was estimated at USD 6.3 billion in 2023 and is expected to reach USD 50.2 billion by 2032 at a CAGR of 25.9% during the forecast period of 2024-2032.
The Cardiac Biomarker Testing Market was valued at USD 4.53 billion in 2023 and is expected to grow at a CAGR of 9.47% to reach USD 10.21 billion by 2032.
The Single-Use Bioreactors Market Size was valued at USD 3872.40 million in 2023 and is expected to reach USD 13784.83 million by 2031 and grow at a CAGR of 17.2% over the forecast period 2024-2031.
The Medical Robots Market Size was USD 14.9 billion in 2023 and is expected to reach USD 57.0 billion by 2032 and grow at a CAGR of 16.06% by 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
